

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/080725 A1

(51) International Patent Classification:

C07D 413/04 (2006.01) **C07D 271/06** (2006.01)
C07D 413/14 (2006.01) **A61P 37/00** (2006.01)
C07D 223/16 (2006.01) **A61P 17/00** (2006.01)
C07D 267/14 (2006.01) **A61K 31/55** (2006.01)

(21) International Application Number:

PCT/EP2008/067965

(22) International Filing Date:

19 December 2008 (19.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0725120.0 21 December 2007 (21.12.2007) GB
0821918.0 1 December 2008 (01.12.2008) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEMONT, Emmanuel, Hubert** [FR/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **HEER, Jag, Paul** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **HEIGHTMAN, Thomas, Daniel** [GB/GB]; c/o GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19



5AW (GB). **HURST, David, Nigel** [GB/GB]; c/o GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **JOHNSON, Christopher, Norbert** [GB/GB]; c/o GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **SKIDMORE, John** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **WALL, Ian, David** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **WITHERINGTON, Jason** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB).

(74) Agents: **GRIFFITH, Johanna, Elise** et al.; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)



(57) Abstract: The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (SIP) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R₁ is up to two substituents independently selected from halogen, C₍₁₋₃₎alkoxy, C₍₁₋₃₎fluoroalkyl, cyano, optionally substituted phenyl, C₍₁₋₃₎fluoroalkoxy, C₍₁₋₆₎alkyl and C₍₃₋₆₎Cyctoalkyl; R₂ is hydrogen, halogen or C₍₁₋₄₎alkyl; B is a 7 membered saturated ring selected from the following: Formulae (a) (b) (c) R₃ is hydrogen or (CH₂)₁₋₄MCO₂H; R₄ is hydrogen or C₍₁₋₃₎alkyl optionally interrupted by oxygen;



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report*